MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer
Imported from official source
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).
This version
- Version
- 1 of 1
- Recorded
- November 11, 2026 17:02
- Change
- Initial
- Content hash
b4dc13d2cad2dfde72b67422fb63ccc5- All versions
- Revision history